Pfizer Inc. (PFE) Shares Sold by Princeton Capital Management LLC
Princeton Capital Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 5.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,170 shares of the biopharmaceutical company’s stock after selling 7,128 shares during the quarter. Pfizer makes up 2.4% of Princeton Capital Management LLC’s investment portfolio, making the stock its 14th biggest holding. Princeton Capital Management LLC’s holdings in Pfizer were worth $5,869,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Asymmetry Capital Management L.P. purchased a new stake in Pfizer during the 3rd quarter valued at approximately $3,010,000. Norinchukin Bank The raised its stake in Pfizer by 4.9% during the 3rd quarter. Norinchukin Bank The now owns 1,187,377 shares of the biopharmaceutical company’s stock valued at $52,328,000 after acquiring an additional 55,494 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in Pfizer by 3.6% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 713,904 shares of the biopharmaceutical company’s stock valued at $31,462,000 after acquiring an additional 24,641 shares during the last quarter. LLBH Private Wealth Management LLC raised its stake in Pfizer by 10.1% during the 3rd quarter. LLBH Private Wealth Management LLC now owns 32,360 shares of the biopharmaceutical company’s stock valued at $1,426,000 after acquiring an additional 2,956 shares during the last quarter. Finally, South State Corp raised its stake in Pfizer by 3.0% during the 3rd quarter. South State Corp now owns 258,334 shares of the biopharmaceutical company’s stock valued at $11,385,000 after acquiring an additional 7,415 shares during the last quarter. 70.61% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Douglas M. Lankler sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $42.75, for a total value of $213,750.00. Following the completion of the transaction, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,573,558. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Douglas M. Lankler sold 38,800 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total value of $1,598,172.00. Following the completion of the transaction, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at $3,443,154.48. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Shares of PFE stock opened at $42.40 on Friday. The company has a market cap of $252.40 billion, a PE ratio of 14.13, a price-to-earnings-growth ratio of 2.39 and a beta of 0.77. Pfizer Inc. has a 12-month low of $34.32 and a 12-month high of $46.47. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.01. The business had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a return on equity of 25.38% and a net margin of 20.79%. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.86 earnings per share for the current year.
Pfizer declared that its board has authorized a stock repurchase plan on Friday, December 14th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 3.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, February 1st will be paid a $0.36 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.34. This represents a $1.44 annualized dividend and a yield of 3.40%. The ex-dividend date is Thursday, January 31st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Shares Sold by Princeton Capital Management LLC” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2019/02/17/pfizer-inc-pfe-shares-sold-by-princeton-capital-management-llc.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: What are the risks of holding treasury bonds?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.